Renal denervation is a minimally invasive catheter-based technique. It is a radiofrequency or ultrasound ablation technique used to treat uncontrolled hypertension. Renal denervation is a catheter-based endovascular treatment used to treat hypertension that is uncontrolled by medication. A catheter emits radiofrequency radiation across many electrodes throughout the process. A radiofrequency pulse is delivered to the renal artery, causing the arterial wall to ablate, lowering nerve activity and, as a result, blood pressure. The advancement of catheter-based interventional therapy has shown significant results in validating improved blood pressure control in patients with uncontrolled hypertension, vascular, and cardiovascular illnesses.
Renal denervation is a minimally invasive surgery used to treat drug- or treatment-resistant hypertension. By ablation of the renal nerves, this technique lowers blood pressure. With increased rates of uncontrolled and treatment-resistant hypertension, demand for RDN devices is projected to rise in the coming years. The benefits of the RDN process, such as faster treatment times and durable effects over pharmacological therapy, will also help to drive market expansion. Furthermore, increased understanding of the RDN process and anticipated approvals from regulatory organizations such as the FDA will drive worldwide demand for RDN devices.
According to WHO estimates, more than 1.2 billion people suffered from hypertension in 2012. According to clinical data obtained from various countries, the global prevalence of hypertension is between 38 and 45 percent. Furthermore, according to recent statistics from the National Health and Nutrition Examination Survey (NHANES), the prevalence of hypertension in the United States is about 30%. After analyzing data from numerous clinical trials, it was shown that more than 25% to 45 percent of hypertensive persons had uncontrolled hypertension, and 15% of these people have treatment resistant hypertension. This bodes well for the RDN operation, since it significantly lowers blood pressure in patients with treatment-resistant hypertension, giving a solid foundation for market expansion.